Receive The Newest Study Notifications

SARASOTA, Fla. and NOVATO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc.Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and...

Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a...

BELGRADE, Mont.--(BUSINESS WIRE)--Lattice Biologics Ltd. Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology,...

ENGLEWOOD CLIFFS, N.J., March 17, 2020 /PRNewswire/ -- Enzychem Lifesciences (KOSDAQ: 183490) today announced that it is advancing a domestic clinical trial of EC-18, a new coronavirus treatment candidate, in South Korea. The company has also been in communication...

CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1/1b...

− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging agent since company’s 2018 acquisition − BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company...

Applied Genetic Technologies Corporation has completed enrollment in all dose groups for adult patients with achromatopsia in its phase 1/2 clinical programs, according to a press release. The company is evaluating the safety and efficacy of rAAV2tYF-PR1.7-hCNGA3 in...

A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious...

VANCOUVER, Washington, March 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications,...

A quantitative survey conducted by Continuum Clinical late last week indicates as many as one third of clinical research study sites were anticipating significant COVID-19-related interruptions to clinical trial recruitment and retention rates in the weeks and months...

- Sub-study shows greater than 90% of enrolled patients have moderate to severe periodontal disease, indicating relevance to mechanism of action against P. gingivalis - Interim analysis of the Phase 2/3 GAIN Trial expected to occur before year-end 2020 SOUTH SAN...

– Phase 1B Study Demonstrates the Potential of GS-6207 to Rapidly Reduce Viral Load After a Single Subcutaneous Injection – – Gilead Progresses Long-Acting Therapy Research Program to Help Address Real-World Challenges for People Living with HIV – March 11, 2020 03:09...

EXTON, Pa., March 12, 2020 (GLOBE NEWSWIRE) -Idera Pharmaceuticals, Inc., Inc. (“Idera”) (NASDAQ: IDRA) reported on March 11, 2020 its financial and operational results for the fourth quarter and year ended December 31, 2019. “In 2019, we made great progress with...

SAN DIEGO--(BUSINESS WIRE)-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an interim clinical data update for cirmtuzumab, a ROR1-targeted monoclonal...

Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies,...

PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations SAN...

The Christie NHS Foundation Trust and Innovative Trials, a clinical trial patient recruitment company, has announced a pioneering partnership to tackle the issue of patient diversity within clinical trials and help speed up research so that effective treatments come...

Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company focused on...

SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of sparsentan in focal segmental glomerulosclerosis...

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia, to...